003220 — Daewon Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- KR₩263bn
- KR₩419bn
- KR₩598bn
- 46
- 58
- 23
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.94 | ||
| PEG Ratio (f) | 0.13 | ||
| EPS Growth (f) | 1,281.61% | ||
| Dividend Yield (f) | 2.45% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.44 | ||
| EV to EBITDA | 19.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.05% | ||
| Return on Equity | -5.53% | ||
| Operating Margin | -0.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 308,501.02 | 354,176.44 | 478,884.66 | 526,952.05 | 598,162.35 | 629,233 | 680,233 | 13.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -33.97 | -57.27 | +337.18 | -16.14 | -40.62 | -93.43 | +1931.73 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daewon Pharmaceutical Co Ltd is a Korea-based holding company primarily engaged in the manufacturing and sales of pharmaceuticals business. The Company operates its business through four segments. The Pharmaceutical segment is mainly engaged in the manufacturing and sales of drugs such as Jinhae expectant, antipyretic analgesic, antidote and arteriosclerotic agents. The Cosmetics segment is mainly engaged in the manufacturing and sales of cosmetics such as mask packs and eye patches, which are used for moisturizing the skin. The Health Functional Food segment is mainly engaged in the manufacturing and sales of health functional foods. The Other segment is mainly engaged in the supply of other goods and service services. The Company sells its products in domestic and overseas markets.
Directors
- Seung Ho Baek CHM (57)
- Seon Geun Park PRE (64)
- Seung Yeol Baek VCH (54)
- Jae Ho Kim MDR (53)
- Bon Am Gu MDR (54)
- Jung Hyeon Shin OTH (52)
- Jeong Hui Kim DRC (79)
- Seo Yeong Jung NID (57)
- Hyeon Tae Kim NID (67)
- Hyeong Ju Lee NID (62)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- August 9th, 1961
- Public Since
- December 15th, 1999
- No. of Shareholders
- 21,306
- No. of Employees
- 738
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 21,433,439
- Address
- 386, Cheonho-daero, Seongdong-gu, SEOUL, 04808
- Web
- https://www.daewonpharm.com/main/index.jsp
- Phone
- +82 222047000
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 003220
Daewon Pharmaceutical Co Ltd Annual Shareholders Meeting
Q1 2026 Daewon Pharmaceutical Co Ltd Earnings Release
Similar to 003220
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
What is the Daewon Pharmaceutical Co share price?
As of Today at 10:10 UTC, shares in Daewon Pharmaceutical Co are trading at KR₩12,250. This share price information is delayed by 15 minutes.
How has the Daewon Pharmaceutical Co share price performed this year?
Shares in Daewon Pharmaceutical Co last closed at KR₩12,250 and the price had moved by -12.69% over the past 365 days. In terms of relative price strength the Daewon Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -32.67% over the past year.
What are the analyst and broker recommendations for Daewon Pharmaceutical Co?
The overall consensus recommendation for Daewon Pharmaceutical Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Daewon Pharmaceutical Co dividend yield?
The Daewon Pharmaceutical Co dividend yield is 2.45% based on the trailing twelve month period.
Does Daewon Pharmaceutical Co pay a dividend?
Last year, Daewon Pharmaceutical Co paid a total dividend of KR₩300, and it currently has a trailing dividend yield of 2.45%. We do not have any data on when Daewon Pharmaceutical Co is to next pay dividends.
When does Daewon Pharmaceutical Co next pay dividends?
We do not have data on when Daewon Pharmaceutical Co is to next pay dividends. The historic dividend yield on Daewon Pharmaceutical Co shares is currently 2.45%.
How do I buy Daewon Pharmaceutical Co shares?
To buy shares in Daewon Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Daewon Pharmaceutical Co?
As of the previous close price of KR₩12,250, shares in Daewon Pharmaceutical Co had a market capitalisation of KR₩263bn.
Where are Daewon Pharmaceutical Co shares listed?
Here are the trading details for Daewon Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 003220
What kind of share is Daewon Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Daewon Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Daewon Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Daewon Pharmaceutical Co is KR₩16,000. That is 30.61% above the last closing price of KR₩12,250.
Analysts covering Daewon Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩52 for the next financial year.
Find out moreWhat is the trend in the Daewon Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daewon Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.51%.
As of the last closing price of KR₩12,250, shares in Daewon Pharmaceutical Co were trading -7.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Daewon Pharmaceutical Co PE Ratio?
The Daewon Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 11.94. The shares last closed at KR₩12,250.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Daewon Pharmaceutical Co?
Daewon Pharmaceutical Co's management team is headed by:
- Seung Ho Baek - CHM
- Seon Geun Park - PRE
- Seung Yeol Baek - VCH
- Jae Ho Kim - MDR
- Bon Am Gu - MDR
- Jung Hyeon Shin - OTH
- Jeong Hui Kim - DRC
- Seo Yeong Jung - NID
- Hyeon Tae Kim - NID
- Hyeong Ju Lee - NID